

Sherwin K. B. Sy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/672582/publications.pdf>

Version: 2024-02-01

61
papers

970
citations

430874

18
h-index

552781

26
g-index

61
all docs

61
docs citations

61
times ranked

1277
citing authors

#	ARTICLE	IF	CITATIONS
1	Florfenicol/Chlortetracycline Effect on Pharmacodynamic Indices for Mutant Selection of <i>Riemerella anatispestifer</i> in Ducks. <i>Microbial Drug Resistance</i> , 2022, 28, 832-840.	2.0	3
2	Model-informed drug development for immunology agonistic anti-GITR antibody <scp>GWN323</scp>: Dose selection based on <scp>MABEL</scp> and biologically active dose. <i>Clinical and Translational Science</i> , 2022, 15, 2218-2229.	3.1	4
3	Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1393-1403.	3.5	6
4	Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 1040-1050.	4.7	8
5	Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1012-1023.	2.4	15
6	Pharmacokinetic-Pharmacodynamic Characterization of a Topical Photochemotherapy Using <i>Brosimum gaudichaudii</i> in C56BL/6 Mice. <i>Revista Brasileira De Farmacognosia</i> , 2021, 31, 184-192.	1.4	0
7	Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> harbouring serine- and New Delhi metallo- β -lactamases. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2875-2883.	3.0	14
8	Learning and augmenting natural processes: potential means of combating antimicrobial resistance from a drug R&D perspective. <i>Drug Discovery Today</i> , 2020, 25, 1-3.	6.4	10
9	Melanogenic Effect and Toxicity Assessments of Standardized Extract of <i>Brosimum gaudichaudii</i> . <i>Revista Brasileira De Farmacognosia</i> , 2020, 30, 597-601.	1.4	1
10	Application of Trial Simulation in the Design of a Prospective Study for Concentration-QTc Analysis in Support of a Thorough QT Study Waiver. <i>AAPS Journal</i> , 2020, 22, 101.	4.4	1
11	Pharmacokinetics, Pharmacodynamics and Dermal Distribution of 5-Methoxypsoralen Based on a Physiologically Based Pharmacokinetic Model to Support Phytotherapy Using <i>Brosimum gaudichaudii</i> . <i>Planta Medica</i> , 2020, 86, 276-283.	1.3	5
12	Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development. <i>Clinical Pharmacokinetics</i> , 2019, 58, 545-564.	3.5	30
13	Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant <i>Acinetobacter baumannii</i> Using Checkerboard Information. <i>Microbial Drug Resistance</i> , 2019, 25, 1266-1274.	2.0	23
14	Physiologically based pharmacokinetics of ziprasidone in pregnant women. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 914-923.	2.4	15
15	Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against <i>Pseudomonas aeruginosa</i> Producing Metallo- β -Lactamase. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	30
16	Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation. <i>International Journal of Antimicrobial Agents</i> , 2019, 53, 275-283.	2.5	21
17	Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar Development. <i>AAPS Journal</i> , 2018, 20, 40.	4.4	9
18	Change in Topoisomerase β -Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. <i>Clinical Cancer Research</i> , 2018, 24, 3348-3357.	7.0	18

#	ARTICLE	IF	CITATIONS
19	A mathematical model-based analysis of the time-kill kinetics of ceftazidime/avibactam against <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1295-1304.	3.0	24
20	Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 897-909.	2.3	2
21	Fixed-dose combinations: a potential means to boost drug development for selected drugs. <i>Drug Discovery Today</i> , 2018, 23, 457-459.	6.4	14
22	Experimental design and modelling approach to evaluate efficacy of β -lactam/ β -lactamase inhibitor combinations. <i>Clinical Microbiology and Infection</i> , 2018, 24, 707-715.	6.0	16
23	<i>Mycobacterium tuberculosis</i> Strains H37ra and H37rv have equivalent minimum inhibitory concentrations to most antituberculosis drugs. <i>International Journal of Mycobacteriology</i> , 2018, 7, 156.	0.6	48
24	Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors. <i>Clinical Pharmacokinetics</i> , 2017, 56, 65-76.	3.5	21
25	Prediction of <i>in vivo</i> and <i>in vitro</i> infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 197-207.	2.5	24
26	Potential of ceftazidime by avibactam against β -lactam-resistant <i>Pseudomonas aeruginosa</i> in an <i>in vitro</i> infection model. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw535.	3.0	18
27	Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 57-67.	2.3	6
28	Pharmacodynamic Evaluation of Fosfomycin against <i>Escherichia coli</i> and <i>Klebsiella</i> spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	26
29	Rapid and efficient method for the quantification of lychnopholide in rat plasma by liquid chromatography-tandem mass spectrometry for pharmacokinetic application. <i>Biomedical Chromatography</i> , 2016, 30, 1092-1096.	1.7	2
30	Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4128-4139.	3.2	37
31	<i>In vitro</i> pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1866-1880.	3.0	35
32	Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 93-114.	3.3	46
33	Pharmacokinetics I: PK-PD Approach, the Case of Antibiotic Drug Development. , 2016, , 185-217.		7
34	Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1012-1021.	3.0	21
35	Quantitation of the impact of CYP3A5 A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 387-394.	1.6	8
36	<i>N</i> -Acetyltransferase Genotypes and the Pharmacokinetics and Tolerability of <i>para</i> -Aminosalicylic Acid in Patients with Drug-Resistant Pulmonary Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 4129-4138.	3.2	27

#	ARTICLE	IF	CITATIONS
37	Effect of reducing the paediatric stavudine dose by half: A physiologically-based pharmacokinetic model. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 413-419.	2.5	11
38	Characterization of intestinal absorption of C-glycoside flavonoid vicenin-2 from <i>Lychnophora ericoides</i> leaves in rats by nonlinear mixed effects modeling. <i>Revista Brasileira De Farmacognosia</i> , 2015, 25, 212-218.	1.4	14
39	Evaluation of in vitro synergy between vertilmicin and ceftazidime against <i>Pseudomonas aeruginosa</i> using a semi-mechanistic pharmacokinetic/pharmacodynamic model. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 151-160.	2.5	21
40	Pharmacokinetic Evaluation of Avicularin Using a Model-Based Development Approach. <i>Planta Medica</i> , 2015, 81, 373-381.	1.3	8
41	Simultaneous Characterization of Intravenous and Oral Pharmacokinetics of Lychnopholide in Rats by Transit Compartment Model. <i>Planta Medica</i> , 2015, 81, 1121-1127.	1.3	8
42	Largazole Pharmacokinetics in Rats by LC-MS/MS. <i>Marine Drugs</i> , 2014, 12, 1623-1640.	4.6	15
43	Estimation of Intracellular Concentration of Stavudine Triphosphate in HIV-Infected Children Given a Reduced Dose of 0.5 Milligrams per Kilogram Twice Daily. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1084-1091.	3.2	9
44	Predicting Pediatric Age-Matched Weight and Body Mass Index. <i>AAPS Journal</i> , 2014, 16, 1372-1379.	4.4	15
45	Pharmacokinetics of <i>para</i> -Aminosalicylic Acid in HIV-Uninfected and HIV-Coinfected Tuberculosis Patients Receiving Antiretroviral Therapy, Managed for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 6242-6250.	3.2	31
46	Introduction to Pharmacometrics and Quantitative Pharmacology with an Emphasis on Physiologically Based Pharmacokinetics. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , 1-64.	0.6	8
47	Principles of Applied Pharmacokineticâ€“Pharmacodynamic Modeling. , 2014, , 63-79.		10
48	Pharmacometrics in Bacterial Infections. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2014, , 229-258.	0.6	13
49	A Markov Chain Model to Evaluate the Effect of CYP3A5 and ABCB1 Polymorphisms on Adverse Events Associated with Tacrolimus in Pediatric Renal Transplantation. <i>AAPS Journal</i> , 2013, 15, 1189-1199.	4.4	13
50	Influence of <i>CYP3A5</i> 6986Aâ€“G and <i>ABCB1</i> 3435Câ€“T Polymorphisms on Adverse Events Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 67-78.	1.6	5
51	Electroencephalogram effects of armodafinil: Comparison with behavioral alertness. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1058-1071.	2.0	4
52	In silico labeling reveals the time-dependent label half-life and transit-time in dynamical systems. <i>BMC Systems Biology</i> , 2012, 6, 13.	3.0	6
53	Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 899-908.	1.9	32
54	Use of a sparse sampling study design to assess transfer of tramadol and its O-desmethyl metabolite into transitional breast milk. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 661-666.	2.4	53

#	ARTICLE	IF	CITATIONS
55	A Perspective on the Toxicological Mechanisms Possibly Contributing to the Failure of Oral Glycoprotein IIb/IIIa Antagonists in the Clinic. <i>American Journal of Cardiovascular Drugs</i> , 2004, 4, 1-10.	2.2	3
56	Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003, 31, 937-951.	2.8	15
57	The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease. <i>American Journal of Cardiovascular Drugs</i> , 2003, 3, 101-112.	2.2	18
58	Safety, Tolerability, Pharmacokinetics, and Time Course of Pharmacologic Response of the Active Metabolite of Roxifiban, XV459, a Glycoprotein IIb/IIIa Antagonist, following Oral Administration in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 738-753.	2.0	12
59	Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 357-365.	1.9	38
60	Multivariate cluster analysis of a human hepatic cytochrome P 450 database. <i>European Journal of Clinical Pharmacology</i> , 2002, 58, 559-562.	1.9	3
61	Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 377-386.	1.9	10